Herpes simplex virus type-2 assay specificity and male circumcision to reduce herpes simplex virus type-2 acquisition

Tobian, Aaron A.R.a,b,c; Kigozi, Godfreyc; Wawer, Maria J.b,c; Serwadda, Davidc,d; Quinn, Thomas C.c,e,f; Gray, Ronald H.b,c

doi: 10.1097/QAD.0b013e32835aa181
Author Information

aDepartment of Pathology, School of Medicine

bDepartment of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA

cRakai Health Sciences Program, Entebbe

dSchool of Public Health, Makerere University, Kampala, Uganda

eDepartment of Medicine, School of Medicine, Johns Hopkins University, Baltimore

fDivision of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Correspondence to Aaron Tobian, MD, PhD, Department of Pathology, Johns Hopkins University, Carnegie 437, 600 N. Wolfe St., Baltimore, MD 21287, USA. Tel: +1 443 287 0527; e-mail: atobian1@jhmi.edu

Received 15 June, 2012

Accepted 21 September, 2012

Article Outline

Three male circumcision trials which enrolled over 10 000 men of different ages, settings (urban vs. rural), and countries (Uganda, Kenya, and South Africa), and which utilized different surgical techniques were consistent in showing a 51–60% reduction in HIV incidence [1–5], and all three trials reported that male circumcision decreased high-risk human papillomavirus (HR-HPV) prevalence by 32–35% [6–8].

In addition, both the Ugandan and Kenyan trials showed that male circumcision reduced genital ulcer disease by 47–48% [1,9]. As the majority of genital ulcers in both men and women are due to herpes simplex virus type-2 (HSV-2) [10–12], it was hypothesized that male circumcision also reduces HSV-2 acquisition. The Ugandan and South African trials evaluated this hypothesis and reported that male circumcision reduced HSV-2 incidence by 25–34% [8,13]. Interestingly, however, Mehta et al.[9] did not find similar efficacy in the Kenyan trial in Kisumu.

All three trials utilized an ELISA manufactured by Kalon Biological (Guildford, UK) to detect incident HSV-2. However, interpretation of this assay to detect HSV-2 seroconversion can be problematic, because the index value to define a positive result may differ from the manufacturer's recommended cutoff based on European and North American populations and HSV-2 viruses [14]. There are multiple reports of high false-positive rates among African samples [14–18]. We and others found that a higher index cutoff value is required for optimal sensitivity and specificity [14,16,19]. When used according to manufacturer's instructions (index cutoff value 1.1), the Kalon ELISA had a sensitivity of 95.1% and a specificity of only 87.6% in Uganda compared to western blot [14], whereas a Kalon index value cutoff of 1.5 resulted in a sensitivity of 91.7% and a specificity of 92.4% [14]. Specificity increased to 97.6% with an index value of 2.5 and 98.4% with an index value of 3.5 [14]. In a validation study among men enrolled in the male circumcision trial in Kisumu, the Kalon ELISA at the recommended manufacturer's cutoff had low sensitivity (92%) and specificity (79%) [20]. In their analysis, Mehta et al.[9] used the manufacturer's cutoff to evaluate the efficacy of male circumcision to reduce HSV-2 incidence, a cutoff which is likely to have reduced specificity and may have biased their results toward the null.

Mehta et al.[9] noted that ‘no differences were found between circumcised and uncircumcised men at other cutoff values of 1.5, 2.0, 2.5, 3.0, and 3.5.’ However, to determine whether improved specificity affected male circumcision efficacy estimates in the Ugandan trial, we assessed HSV-2 seroconverters classified by higher Kalon ELISA index values which maximize specificity and reduce potential false positives. For HSV-2 seroconversion rate and person time calculations, it was assumed that HSV-2 infection occurred at the mid-time point between the last negative and first positive serological tests. Time from enrollment was accumulated to the 24-month follow-up visit or the last available sample visit, and HSV-2 seroconversions were estimated per 100 person-years. Incidence rate ratios and 95% confidence intervals were estimated using Poisson regression.

As HSV-2 assay specificity increased, male circumcision efficacy to prevent HSV-2 infection increased, though modestly (Table 1). Thus, the previously reported 25–34% reduction in HSV-2 from the Ugandan and South African trials likely represent conservative estimates.

As Mehta et al. note in the discussion, the lack of an association between male circumcision and reduced incident HSV-2 in the Kenyan trial may be due to poor test performance. The results of the Ugandan and Kenyan trials showing reduced genital ulceration following male circumcision and the results of the Ugandan and South African male circumcision trials showing reduced HSV-2 acquisition appear consistent. The analysis in Table 1 suggests that higher assay specificity further strengthens the observed associations that male circumcision reduces both HSV-2 incidence and genital ulcer disease.

Back to Top | Article Outline


Conflicts of interest

There are no conflicts of interest.

Back to Top | Article Outline


1. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007; 369:657–666.
2. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007; 369:643–656.
3. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005; 2:e298.
4. Tobian AA, Gray RH. The medical benefits of male circumcision. JAMA 2011; 306:1479–1480.
5. Tobian AA, Gray RH, Quinn TC. Male circumcision for the prevention of acquisition and transmission of sexually transmitted infections: the case for neonatal circumcision. Arch Pediatr Adolesc Med 2010; 164:78–84.
6. Auvert B, Sobngwi-Tambekou J, Cutler E, Nieuwoudt M, Lissouba P, Puren A, et al. Effect of male circumcision on the prevalence of high-risk human papillomavirus in young men: results of a randomized controlled trial conducted in Orange Farm, South Africa. J Infect Dis 2009; 199:14–19.
7. Smith J, Backes DM, Bailey R, Moses S, Agot K, Maclean IW, et al.The effect of male circumcision on incident and persistent penile HPV infections in men from Kenya.26th International Papillomavirus Conference 2010.
8. Tobian AA, Serwadda D, Quinn TC, Kigozi G, Gravitt PE, Laeyendecker O, et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med 2009; 360:1298–1309.
9. Mehta SD, Moses S, Parker CB, Agot K, Maclean I, Bailey RC. Circumcision status and incident herpes simplex virus type 2 infection, genital ulcer disease, and HIV infection. AIDS 2012; 26:1141–1149.
10. Suntoke TR, Hardick A, Tobian AA, Mposa B, Laeyendecker O, Serwadda D, et al. Evaluation of multiplex real-time PCR for detection of H. ducreyi, T. pallidum, HSV-1, and HSV-2 in the diagnosis of genital ulcer disease in Rakai District, Uganda. Sex Transm Infect 2009; 85:97–101.
11. Brankin AE, Tobian AA, Laeyendecker O, Suntoke TR, Kizza A, Mpoza B, et al. Aetiology of genital ulcer disease in female partners of male participants in a circumcision trial in Uganda. Int J STD AIDS 2009; 20:650–651.
12. Tobian AAR, Charvat B, Ssempijja V, Kigozi G, Serwadda D, Makumbi F, et al. Factors associated with the prevalence and incidence of herpes simplex virus type 2 infections among men in Rakai, Uganda. J Infect Dis 2009; 199:945–949.
13. Sobngwi-Tambekou J, Taljaard D, Lissouba P, Zarca K, Puren A, Lagarde E, et al. Effect of HSV-2 serostatus on acquisition of HIV by young men: results of a longitudinal study in Orange Farm, South Africa. J Infect Dis 2009; 199:958–964.
14. Gamiel JL, Tobian AAR, Laeyendecker OB, Reynolds SJ, Morrow RA, Serwadda D, et al. Improved performance of enzyme-linked immunosorbent assays and the effect of human immunodeficiency virus coinfection on the serologic detection of herpes simplex virus type 2 in Rakai, Uganda. Clin Vaccine Immunol 2008; 15:888–890.
15. Hogrefe W, Su X, Song J, Ashley R, Kong L. Detection of herpes simplex virus type 2-specific immunoglobulin G antibodies in African sera by using recombinant gG2, western blotting, and gG2 inhibition. J Clin Microbiol 2002; 40:3635–3640.
16. Laeyendecker O, Henson C, Gray RH, Nguyen RH, Horne BJ, Wawer MJ, et al. Performance of a commercial, type-specific enzyme-linked immunosorbent assay for detection of herpes simplex virus type 2-specific antibodies in Ugandans. J Clin Microbiol 2004; 42:1794–1796.
17. van Dyck E, Buve A, Weiss HA, Glynn JR, Brown DW, De Deken B, et al. Performance of commercially available enzyme immunoassays for detection of antibodies against herpes simplex virus type 2 in African populations. J Clin Microbiol 2004; 42:2961–2965.
18. Gorander S, Mbwana J, Lyamuya E, Lagergard T, Liljeqvist JA. Mature glycoprotein G presents high performance in diagnosing herpes simplex virus type 2 infection in sera of different Tanzanian cohorts. Clin Vaccine Immunol 2006; 13:633–639.
19. Ashley-Morrow R, Nollkamper J, Robinson NJ, Bishop N, Smith J. Performance of focus ELISA tests for herpes simplex virus type 1 (HSV-1) and HSV-2 antibodies among women in ten diverse geographical locations. Clin Microbiol Infect 2004; 10:530–536.
20. Smith JS, Bailey RC, Westreich DJ, Maclean I, Agot K, Ndinya-Achola JO, et al. Herpes simplex virus type 2 antibody detection performance in Kisumu, Kenya, using the Herpeselect ELISA, Kalon ELISA, western blot and inhibition testing. Sex Transm Infect 2009; 85:92–96.
© 2013 Lippincott Williams & Wilkins, Inc.